A study comparing a two minute injection of the anti-thrombosis agent APSAC with a one hour injection of intra-coronary streptokinase is now underway at 15 hospitals, including the University of Rochester and the University of Utah. Beecham states that its new clot-dissolving agent "differs from other investigational and existing drugs in that it can be administered in a single five-minute injection into a vein." In a recent Phase II dose-response study of 29 heart attack patients conducted by Victor Marder, University of Rochester, the drug dissolved coronary clots in about 60% of the patients. . . .
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.